k 2008

Proteomic Analysis of Multiple Myeloma Cells Targeted with Bortezomib

HÁJEK, Roman, Jana ČUMOVÁ, Anna POTÁČOVÁ, Irena KASALOVÁ, Ondrej ŠEDO et. al.

Basic information

Original name

Proteomic Analysis of Multiple Myeloma Cells Targeted with Bortezomib

Name in Czech

Proteomická analýza lidských myelomových buněk ovlivněných přídavkem bortezomibu

Authors

HÁJEK, Roman, Jana ČUMOVÁ, Anna POTÁČOVÁ, Irena KASALOVÁ, Ondrej ŠEDO and Zbyněk ZDRÁHAL

Edition

ESH Conference. Mechanisms of cell death and disease: advances in therapeutic intervention and drug development. 2008

Other information

Language

English

Type of outcome

Prezentace na konferencích

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Science

Keywords in English

Multiple Myeloma; Bortezomib; proteomics

Tags

International impact
Změněno: 11/4/2010 12:05, Mgr. Anna Potáčová, Ph.D.

Abstract

V originále

Introduction: Multiple myeloma (MM) is still an incurable disease characterized by the clonal expansion of malignant plasma cells. New anticancer drugs further improve prognosis of myeloma patients. Despite promising clinical activity, some patients with MM failed to respond to bortezomib therapy. The aim of this study was to evaluate changes in protein expression of myeloma cell line ARH-77 after bortezomib treatment. Materials and methods: Myeloma cell line ARH-77 was treated with bortezomib (5 – 20nM) for various periods of time. The proteins contained in total myeloma cell lysate were separated by 2-dimensional polyacrylamide gel electrophoresis (2-DE) and the differentially expressed proteins between the untreated (control) and treated cell lines were excised and identified by mass spectrometry. Results: There were analyzed 94 proteins differentially expressed between treated and control cells; total of 34 protein spots were upregulated: proteins involved in regulation of apoptosis, chaperons/stress related proteins, proteolysis of ubiquitin/protein degradation and cytoskeleton proteins. Sixty protein spots were downregulated: proteins involved in synthesis, regulation of apoptosis, chaperons/stress related proteins, regulation of cell cycle proteins, proteins connected to glycolysis and proteolysis of ubiquitin/protein degradation and antioxidant/redox proteins. Conclusion: Employing optimized proteomic approach we identified 94 proteins with altered expression after bortezomib treatment.

Links

LC06027, research and development project
Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622415, plan (intention)
Name: Molekulární podstata buněčných a tkáňových regulací
Investor: Ministry of Education, Youth and Sports of the CR, Molecular basis of cell and tissue regulations
MSM0021622434, plan (intention)
Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
NR9317, research and development project
Name: Prognostický význam klonálních chromosomových aberací při použití nových léčebných metod u mnohočetného myelomu